Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments - CRM - Centre de recherche en myologie - U974
Article Dans Une Revue Orphanet Journal of Rare Diseases Année : 2024

Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments

1 TIMONE - Hôpital de la Timone [CHU - APHM]
2 Service de neurologie [Bordeaux]
3 Centre Hospitalier Universitaire Hôtel Dieu - Centre de Référence Maladies Neuromusculaires AOC
4 LilNCog - Lille Neurosciences & Cognition - U 1172
5 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
6 FSHD registry - France - Observatoire National Français des patients atteints de DMFSH
7 Centre de recherche en Myologie – U974 SU-INSERM
8 CHU Pitié-Salpêtrière [AP-HP]
9 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
10 INM - Institut des Neurosciences de Montpellier
11 CRIBL - Contrôle de la Réponse Immune B et des Lymphoproliférations
12 Hôpital Raymond Poincaré (Garches) [GHU AP-HP Université Paris-Saclay]
13 Groupe hospitalier Pellegrin
14 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
15 Service de neurologie [Angers]
16 HCL - Hospices Civils de Lyon
17 INMG-AR - Institut NeuroMyoGène - Appui à la recherche
18 CHU Nice - Centre Hospitalier Universitaire de Nice
19 U955 Inserm - UPEC - IMRB - "Biologie du système neuromusculaire" [Créteil]
20 Hôpital Henri Mondor
21 Service de Neurophysiologie Clinique (CHU Dijon)
22 CSGA - Centre des Sciences du Goût et de l'Alimentation [Dijon]
23 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
24 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
25 Hôpital Raymond Poincaré [AP-HP]
26 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse

Résumé

Background In 2017, a new treatment by nusinersen, an antisense oligonucleotide delivered by repeated intrathecal injections, became available for patients with spinal muscular atrophy (SMA), whereas clinical trials had mainly involved children. Since 2020, the oral, selective SMN2-splicing modifier risdiplam has been available with restrictions evolving with time. In this peculiar context of lack of data regarding adult patients, many questions were raised to define the indications of treatment and the appropriate follow-up in this population. To homogenize access to treatment in France, a national multidisciplinary team meeting dedicated to adult SMA patients, named SMA multidisciplinary team meeting, (SMDTs) was created in 2018. Our objective was to analyze the value of SMDTs in the decision-making process in SMA adult patients and to provide guidelines about treatment. Methods From October 2020 to September 2021, data extracted from the SMDT reports were collected. The primary outcome was the percentage of cases in which recommendations on validating treatment plans were given. The secondary outcomes were type of treatment requested, description of expectations regarding treatment and description of recommendations or follow-up and discontinuation. Data were analyzed using descriptive statistics. Comparisons between the type of treatment requested were performed using Mann–Whitney test or the Student t test for quantitative data and the Fisher’s exact test or the χ 2 test for qualitative data. Results Cases of 107 patients were discussed at the SMDTs with a mean age of 35.3 (16–62). Forty-seven were SMA type 2, and 57 SMA type 3. Twelve cases were presented twice. Out of 122 presentations to the SMDTs, most of requests related to the initiation of a treatment (nusinersen (n = 46), risdiplam (n = 54), treatment without mentioning preferred choice (n = 5)) or a switch of treatment (n = 12). Risdiplam requests concerned significantly older patients ( p = 0.002), mostly SMA type 2 ( p < 0.0001), with greater disease severity in terms of motor and respiratory function compared to requests for nusinersen. In the year prior to presentation to the SMDTs, most of the patients experienced worsening of motor weakness assessed by functional tests as MFM32 or other meaningful scales for the most severe patients. Only 12% of the patients discussed had a stable condition. Only 49/122 patients (40.1%) expressed clear expectations regarding treatment. The treatment requested was approved by the SMDTs in 72 patients (67.2%). The most common reasons to decline treatment were lack of objective data on the disease course prior discussion to the SMDTs or inappropriate patient’s expectations. Treatment requests were more likely to be validated by the SMDTs if sufficient pre-therapeutic functional assessment had been performed to assess the natural history (55% vs. 32%) and if the patient had worsening rather than stable motor function ( p = 0.029). In patients with approved treatment, a-priori criteria to define a further ineffectiveness of treatment (usually after 14 months of treatment) were proposed for 67/72 patients. Conclusions In the context of costly treatments with few controlled studies in adults with SMA, in whom assessment of efficacy can be complex, SMDTs are ‘real-world observatories’ of great interest to establish national recommendations about indications of treatment and follow-up.
Fichier principal
Vignette du fichier
salort-campana_2024_vol19_24_ojrd.pdf (10.5 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04667757 , version 1 (05-08-2024)

Licence

Identifiants

Citer

Emmanuelle Salort-Campana, Guilhem Solé, Armelle Magot, Céline Tard, Jean-Baptiste Noury, et al.. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments. Orphanet Journal of Rare Diseases, 2024, 19 (1), pp.24. ⟨10.1186/s13023-023-03008-6⟩. ⟨hal-04667757⟩
94 Consultations
7 Téléchargements

Altmetric

Partager

More